Venus Medtech, a Hangzhou medical device maker, closed its merger with Keystone Heart, a private Israeli-US company that makes TriGuard 3™, a cerebral embolic protection device. In 2017, Venus acquired China rights to use the TriGuard to protect against cerebral embolisms during use of Venus’ own transaortic valve replacement product, the first TAVR approved in China. The Keystone device is designed to protect all brain regions in patients undergoing cardiac procedures. Terms of the agreement were not disclosed.
Source: China Biotoday
